Rhianne Voogd

PAIR-Scan: Single-step identification of highly potent TCR–neoantigen pairs through library-on-library screening

Marius Messemaker, Connor A. Richterich, Jule Wenner, Yiting Ma et autres

ca, nl, us (code pays fourni par la source)

Proteomics of human cancer-associated T cells identifies regulators of T cell functionality

Kaspar Bresser, Žan Hozjan, Nila H. Servaas, Suzan Stelloo et autres

nl (code pays fourni par la source)

NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy

Divya Lenkala, Jessica Kohler, Brian McCarthy, Michael S. Nelson et autres

us, nl, de (code pays fourni par la source)

Data from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem, Alberto Gil-Jimenez, Hamza Ali, Jeroen van Dorp et autres

Supplementary Figure S4 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem, Alberto Gil-Jimenez, Hamza Ali, Jeroen van Dorp et autres

Supplementary Figure S6 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem, Alberto Gil-Jimenez, Hamza Ali, Jeroen van Dorp et autres

Supplementary Figure S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem, Alberto Gil-Jimenez, Hamza Ali, Jeroen van Dorp et autres

Supplementary Figure S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem, Alberto Gil-Jimenez, Hamza Ali, Jeroen van Dorp et autres

Supplementary Table S1 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem, Alberto Gil-Jimenez, Hamza Ali, Jeroen van Dorp et autres

Supplementary Table S3 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem, Alberto Gil-Jimenez, Hamza Ali, Jeroen van Dorp et autres

Supplementary Table S2 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem, Alberto Gil-Jimenez, Hamza Ali, Jeroen van Dorp et autres

Supplementary Figure S3 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Chantal F. Stockem, Alberto Gil-Jimenez, Hamza Ali, Jeroen van Dorp et autres